Category: Federal Forum Posters
Purpose: Regorafenib and trifluridine/tipiracil (TAS-102) are indicated as monotherapy for the treatment of adult patients with metastatic colorectal cancer (mCRC) refractory to standard therapy. Little evidence exists about the use of regorafenib in mCRC refractory to TAS-102.
Our purpose is to study the effectiveness and safety of regorafenib in patients with advanced mCRC refractory to TAS-102 in real clinical practice.
Methods: A retrospective observational study including all patients with mCRC who started treatment with regorafenib after TAS-102 between January 2018 and September 2018 was carried out.
The following variables were collected: sex, age, KRAS-mutation, the Eastern Cooperative Oncology Group scale (ECOG) at the beginning of treatment, number of previous lines and adverse effects (AEs).
Median progression-free survival (PFS) and overall survival (OS) were recorded to evaluate effectiveness. Differences in survival were evaluated with the Kaplan-Meier test.
Results: Our study included 4 patients (3 women) with a mean age of 50,9 (45-61). They presented an ECOG 1 in all cases and they had received at least 4 prior lines and a maximum of 7 for mCRC. All of them presented a KRAS-mutation but one. The median PFS was 4.33 (3–9) months and one patient died after 3 months of being treated.
Treatments were discontinued in 3 of those patients following disease progression or patient’s death and none of them because of toxicity.
The AEs related to regorafenib were asthenia (n=3), neutropenia (n=3), infection (n=3), edema (n=1), nausea (n=1), constipation (n=1), bleeding (n=1) and anorexia (n=1). Despite the number of AEs, only in one case they reach a grade 3. In this case, asthenia was de AE grade 3 presented.
Conclusion: We had found regorafenib after TAS102 with a modest effectiveness (PFS 4.33 months) and a tolerable toxicity for patients with refractory mCRC. Similar results have been found in other study already published (1) where they conclude a median PFS of 3,7 months in 10 Asian patients treated with regorafenib after TAS102.
Further investigations with more patients will be needed to assess these results.
1. Tanaka A, Sadahiro S, Suzuki T, Okada K, Saito G, Miyakita H. Retrospective study of regorafenib and trifluridine / tipiracil efficacy as a third ‑ line or later chemotherapy regimen for refractory metastatic colorectal cancer. 2018;6589–97.
Jaime Cordero-Ramos– Resident, Andalusian health system (SAS), Seville, Andalucia, Spain